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Abstract 
Substituted indole-3-acetic acid (IAA) derivatives, plant auxins with potential for use 
as prodrugs in enzyme-prodrug directed cancer therapies, were oxidised with 
horseradish peroxidase (HRP) and toxicity against V79 Chinese hamster lung 
fibroblasts was determined.  Rate constants for oxidation by HRP compound I were 
also measured.  Halogenated IAAs were found to be the most cytotoxic, with typical 
surviving fractions of <10-3 after incubation for 2 hours with 100 µM prodrug and 
HRP.  
 
Introduction 
The oxidation of the plant auxin indole-3-acetic acid (IAA) 1 (Figure 1) with 
horseradish peroxidase (HRP) has been extensively studied, and the mechanism is 
known to be complex.1-5  The products have been shown to be inhibitory towards 
bacterial growth6 and it has recently been shown that HRP oxidation of IAA produces 
a mammalian cell cytotoxin which causes damage to plasmid DNA.7, 8  The low 
toxicity of IAA and the fact that it is not readily oxidised by endogenous mammalian 
peroxidases make it a suitable candidate for use in an enzyme-directed anticancer 
prodrug therapy.9
A previous study of some commercially available substituted IAA derivatives showed 
that, although it was possible to predict the relative rates of oxidation by HRP, there 
was no correlation between rate of oxidation and cytotoxicity.10  Recently it was 
found that 5-fluoroindole-3-acetic acid, although a very poor substrate for HRP and 
slow to oxidise, gave very high cytotoxicity upon activation.11,12  A number of other 
substituted indole-3-acetic acids were then synthesised in order to investigate further 
this unexpected result and develop a lead prodrug for in vivo studies, with the working 
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hypothesis that prodrugs substituted with halogens or other electron-withdrawing 
groups would exhibit improved cytotoxicity compared to IAA itself.   
 
Methods 
Substituted IAAs were synthesised using standard literature procedures or adaptations 
of published methodologies. 1-Methyl-, 5-fluoro-, 5-bromo-, and 5-benzyloxy- 
indole-3-acetic acids were purchased from Sigma-Aldrich, Poole, UK. 
A number of indole-3-acetic acids with mono- or disubstitution in positions 4 - 7 (2a-
h) were synthesised via a Fischer cyclisation (Scheme 1).13, 14, 15   
Other substituted IAAs, which could not be unambiguously synthesised or gave poor 
yields by the Fischer method, were obtained by the direct 3-alkylation of the 
appropriate substituted indole.  7-Chloroindole was purchased from Lancaster 
Synthesis, Lancaster, UK, 5-iodoindole was purchased from Avocado, Port 
Heynsham, UK.  Other haloindoles were synthesised by the Leimgruber-Batcho 
method (Scheme 3).16  Arylindoles were obtained by a Suzuki coupling of 5-
bromoindole.17  The introduction of the acetic acid side chain was carried out via 
alkylation of the zinc salt followed by saponification of the ester to give the 
substituted IAAs 3a – 3h (Scheme 2).18  N-Methylated compounds 4a and 4b were 
also prepared using sodium hydride / iodomethane (Scheme 3). 
Each IAA derivative was oxidised with HRP, and the cytotoxicity against Chinese 
hamster lung fibroblasts (V79 cells) was determined by a clonogenic assay as 
previously described.8  Cells were treated with 2 mL indoles (50 µM or 100 µM) and 
HRP (1.2 µg/mL) for 0-2 h, then washed and left to form colonies for 7 days. After 
growth, colonies were fixed with 75 % methanol and stained with 1 % (w/v) crystal 
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violet. Colonies containing >50 cells were counted and surviving fractions (SF) 
calculated relative to untreated controls. 
The measurement of the rate of reaction of each IAA with HRP compound I, formed 
from a one second premixing of equimolar HRP and hydrogen peroxide (0.47 - 0.76 
µM), was carried out as previously described, at pH 7, using double-mix stopped-flow 
spectrophotometry, monitoring the formation of HRP compound II at 411 nm.8, 10, 19 
Five experiments were averaged and fitted to first order kinetics. Rate constants were 
calculated from the linear plots of first-order rate constants against five IAA 
concentrations. 
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Results and Discussion 
Results are shown in Table 1, with the results for the previously studied IAA 
derivatives given as a comparison.11,19  No toxicity was seen when cells were 
incubated with either HRP or 100µM prodrug alone.    
 
Rates of oxidation are broadly in line with mechanistic predictions, i.e. the presence 
of electron-donating groups enhances the rate of oxidation by HRP compound I.  
Oxidation rates show some variation with substituent position.  There is no direct 
correlation between rate of oxidation  and subsequent toxicity, although many of the 
monosubstituted IAAs that are cytotoxic have an oxidation rate constant in the range 
5 x 102 – 5 x 103 M-1s-1.  Disubstituted halogenated IAAs were generally not toxic 
after oxidation.  The results seem to indicate that both steric and electronic effects 
may be involved, as prodrugs with similar oxidation rates show a wide variation in 
subsequent cytotoxicity.  For example, it is interesting to note that 4-chloro-IAA 3c 
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and 5-chloro-IAA 2c have equal rates of oxidation, but oxidation of 3c results in no 
observable toxicity whereas the products of oxidation of 2c give a cell surviving 
fraction of 3 x 10-3.  Prodrugs that are very slowly oxidised (k < 1 x 103 M-1 s-1) gave 
little cytotoxicity, with the notable exception of 5-fluoro-IAA.  In these cases, the 
slow turnover of the prodrug by HRP may limit any cytotoxic effect of the products 
generated. 
6-Chloro IAA 3f exhibited the highest toxicity upon HRP activation, with further 
experiments using 50 µM prodrug plus HRP giving a measured cell surviving fraction 
after 2 hours incubation of 8.5 x 10-4.  This analogue is now the lead prodrug for 
further studies of in vitro and in vivo drug targeting strategies (Figure 2).  Such 
strategies include antibody, gene, or polymer targeting of HRP to tumours (antibody / 
gene / polymer directed enzyme-prodrug therapy; ADEPT, GDEPT, PDEPT) for 
selective activation of the prodrug at the tumour site.11,20,21 
Preliminary studies suggest that 3-methyleneoxindole 5 (Figure 3) is an important 
toxic oxidation product in this system.  It is susceptible to attack by nucleophiles, and 
therefore could react with cellular thiols and also has the potential to be DNA-
binding.11  The presence of electron-withdrawing groups in substituted 3-
methyleneoxindoles would be expected to enhance the toxicity, consistent with the 
general trend observed for substituted IAAs, We are currently investigating the 
synthesis and reactivity of 5 and substituted analogues, and have demonstrated that 
these compounds exhibit toxicities broadly consistent with those of the corresponding 
oxidised prodrugs.22,23  The toxicity of the most rapidly oxidised 2-methyl-substituted 
IAA analogues cannot be explained in terms of an oxindole product, and so it is 
expected that there is at least one other mechanism of toxicity involved, which 
requires further investigation.   
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Conclusion 
Halogenated indole-3-acetic acids, in particular 6-chloro IAA, have been identified as 
potent lead prodrugs for peroxidase-mediated targeted cancer therapy.  The parent 
prodrugs exhibit negligible toxicity at 100µM, and so efficient targeting of the 
activating enzyme has the potential to give a very favourable therapeutic ratio for this 
enzyme-prodrug system. 
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Captions: 
 
Table 1: Oxidation rates of IAA derivatives and cytotoxicity of products 
 
Figure 2: Toxicity of 6-chloroindole-3-acetic acid / HRP combination to V79 cells 
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Rossiter Table 1 
reference substituent Rate constant 
with HRP cmp I 
x 103 M-1s-1(± 
s.e.m)  
Surviving fraction after 
2h incubation, mean (± 
s.e.m), n = 3a
2a 5-CF3O 0.3 ± 0.01 1 
 5-F 0.4 ± 0.0111 < 1 x 10-5
4a 1-Me, 5-F 0.4 ± 0.03 1 
2b 4-Cl, 6-Cl 0.6 ± 0.02 1 
4b 1-Me, 6-Cl 0.9 ± 0.1 1 
3a 7-Cl 0.9 ± 0.1 4 x 10-5 b
3b 4-F 1.0 ± 0.06  9 x 10-5 (± 7 x 10-5) 
3c 4-Cl 1.4 ± 0.01 1 
2c 5-Cl 1.4 ± 0.04 3 x 10-3 (± 2 x 10-3) 
 5-Br 1.7 ± 0.04 4 x 10-5 (± 3 x 10-5) 
3d 6-F 1.8 ± 0.02 1 x 10-2 (± 7 x 10-3) c
 1-Me 3.7 ± 0.03  1 x 10-2 (± 5 x 10-3) 
 none 3.8 ± 0.119 1 x 10-2 (± 5 x 10-3) 
3e 5-I 3.9 ± 0.2 1 
2d 5-Me, 7-F 4.1 ± 0.9 1 
2e 5-Cl, 7-F 5.3 ± 0.4 1 
2f 4-Me, 7-F 5.8 ± 0.3 1 
3f 6-Cl 7.5 ± 0.2 < 1 x 10-5
 5-BnO 21 ± 0.03 0.2 (± 0.1) 
 5-MeO 22 ± 0.119 1 
2g 5-Me 41 ± 2 1 
3g 5-Ph 46 ± 3 1 
2h 2-Me, 5-F 88 ± 3 1 
3h 5-(4-ClC6H4) 103 ± 0.2 1 
 2-Me 435 ± 619 4 x 10-3 (± 2 x 10-3) 
 2-Me, 5-MeO 1710 ± 13019 4 x 10-2 (± 1 x 10-2) 
    
 
a: 100 µM prodrug + 1.2 µg/mL HRP.   
b: n = 1 
c: n = 2 
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Rossiter Scheme 1 
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